A5040690721- Multiple Myeloma Research and Treatments
- Cancer Treatment and Pharmacology
- Prostate Cancer Treatment and Research
- Protein Degradation and Inhibitors
- Prostate Cancer Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Radiopharmaceutical Chemistry and Applications
- Health Systems, Economic Evaluations, Quality of Life
- Musculoskeletal pain and rehabilitation
- Immune Cell Function and Interaction
- Hematopoietic Stem Cell Transplantation
- Amyloidosis: Diagnosis, Treatment, Outcomes
- HIV/AIDS drug development and treatment
- Fibromyalgia and Chronic Fatigue Syndrome Research
- T-cell and Retrovirus Studies
- Workplace Health and Well-being
- Bone health and treatments
- Erythropoietin and Anemia Treatment
- Drug Transport and Resistance Mechanisms
- Hormonal and reproductive studies
- Chronic Myeloid Leukemia Treatments
- Glycosylation and Glycoproteins Research
- Phytochemical compounds biological activities
- Energy and Environmental Sustainability
Karolinska Institutet
2009-2021
Xalud Therapeutics (United States)
2021
CellProtect Nordic Pharmaceuticals (Sweden)
2020
John Wiley & Sons (United States)
2019
Hudson Institute
2019
Karolinska University Hospital
2015
Roche (Sweden)
2008
Stockholm County Council
2006
Few approaches have been made toward exploring autologous NK cells in settings of cancer immunotherapy. Here, we demonstrate the feasibility infusing multiple doses ex vivo activated and expanded patients with myeloma (MM) post-autologous stem cell transplantation. Infused were detected circulation up to 4 weeks after last infusion. Elevations plasma granzyme B levels observed following each consecutive Moreover, increased bone marrow All measurable had objective, detectable responses...
Background: This study investigated prostate cancer (PC)-specific survival and overall (OS) in a population-based castration-resistant PC (CRPC) cohort.Methods: Data from Stockholm Prostate-Specific Antigen (PSA) Biopsy Register patients with increasing PSA despite gonadotropin-releasing hormone treatment or surgical castration (n = 1,712) included values biopsies 2003 to 2015 were linked the National Prostate Cancer Prescribed Drug Register. Kaplan-Meier method estimated PC-specific OS,...
Background Renal impairment is a common feature in multiple myeloma and considered poor prognostic factor. Aim To determine the impact of novel drugs (i.e. bortezomib, lenalidomide thalidomide) treatment patients with renal impairment. The primary endpoint was overall survival secondary endpoints were time to next response. Methods study population included all diagnosed treatment-demanding January 2000 June 2011 at 15 Swedish hospitals. defined as an estimated glomerular filtration rate...
Summary The outcome for multiple myeloma patients has improved since the introduction of bortezomib, thalidomide and lenalidomide. However, studies comparing new conventional treatment include selected patient groups. We investigated consecutive ( n = 1638) diagnosed in a defined period compared survival with gender‐ age‐matched cohort Swedish population 9 340 682). Median overall non‐high‐dose treated was 2·8 years. use or lenalidomide first line therapy predicted significantly longer...
Abstract In the new era of healthcare digitalization, there is a golden opportunity in overlap between digital health and Real-World Evidence (RWE). this commentary, we define RWE investigate their intersection. We describe stages value chain critical to evidence generation process, how these change with technologies opportunities challenges that arise from evolve—including application for stakeholders such as patients, physicians regulators. also discuss current published guidelines...
Abstract Objective To estimate survival in Swedish and Norwegian myelofibrosis (MF) patients who received ruxolitinib. Methods with MF diagnosis the National Cancer Registries (Sweden: 2001‐2015; Norway: 2002‐2016) ≥1 record of ruxolitinib Prescribed Drug (2013‐2017) were included. Patients followed from initiation until death or end follow‐up; those discontinued discontinuation. Relative (RS) excess mortality rate ratios (EMRRs) calculated vs a matched general population. Average loss life...
Abstract This commentary is authored by several industry real-world evidence (RWE) experts, with support from IQVIA, as part of the 'RWE Leadership Forum': a group Industry Leaders who have come together non-competitive partners to understand and respond RWD/E challenges opportunities single expert voice. Here, forum discusses value in bridging disconnect between RTCs RWE, view promoting use RWE RCT environment. endpoints are explored along axes including their clinical relevance measure...
Abstract Chronic graft versus host disease (cGVHD) is a debilitating and costly complication following haemopoietic stem cell transplantation (HSCT). This study describes the economic burden associated with cGVHD. Direct costs specialised healthcare utilisation (inpatient admissions outpatient visits), as well indirect sickness absence-associated productivity loss were estimated in patients who underwent allogeneic HSCT Sweden between 2006 2015, linking population-based health registers. To...
Studies describing treatment utilization for castration-resistant prostate cancer (CRPC) are limited. We aimed to describe the of a contemporary population-based CRPC cohort between 2006 and 2016.We identified 1699 men with PC diagnosis 2005 2015, who developed 2015 in Stockholm region Sweden. Demographic information, stage grade at diagnosis, CRPC, prostate-specific antigen (PSA) nadir, PSA doubling time, rate within 1 year reason stopping therapy, sequence trajectory, overall specific...
Functional iron deficiency is one reason for lack of response to erythropoietin treatment. Concomitant intravenous (IV) supplementation has the potential improve erythropoietin, allowing a decrease in dose requirements. In recent study anaemic, iron-replete patients with lymphoproliferative malignancies (Leukemia, 21, 2007, 627), haemoglobin (Hb) increase and rate were significantly greater receiving epoetin beta concomitant IV compared without (P < 0.05). The present analysis aimed...
Abstract Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant clonal plasma cell disorder, with 1% yearly risk progression to multiple myeloma (MM). Evolution M‐spike and serum free light chain (sFLC) during follow‐up could identify patients at high progression. In this region‐wide study, including 4756 individuals, 987 MGUS were identified, baseline factors as well evolving involved FLC (iFLC) evaluated potential markers for from MM. Furthermore, iFLC assessed...
Induction therapy for multiple myeloma (MM) and remission status before high-dose treatment (HDT) have been shown to be prognostic factors survival outcome, although the optimal induction is yet defined.We conducted a retrospective analysis of impact on outcome after HDT in MM patients. The study included 236 consecutive patients who underwent HDT.One hundred forty-two (62%) were treated with vincristine, doxorubicin dexamethasone (VAD) or cyclophosphamide betamethasone (CyBet) 94 (38%)...
Serum and urine protein electrophoresis (sPEP/uPEP) are the standard methods for monitoring of multiple myeloma (MM). However, a method detection with shorter half-life, such as serum-free light chain (FLC), could detect response or progression earlier. In total, 450 MM patients were assessed in first, second, third line. Response classified according to International working group guidelines. The overall median time partial better was detectable significantly earlier involved free (iFLC)...
The combination of melphalan and prednisone (MP) has been the standard treatment multiple myeloma (MM). Since introduction novel agents, clinical outcome in MM improved. Six randomized prospective studies with thalidomide combined (MPT) compared to MP have performed, most them showing that MPT gives a better response rate median overall survival (OS). Amongst 1843 patients admitted 15 Swedish centres, we selected all treated first, second, third or fourth line therapy, total 888 274 MPT....
Allogeneic transplantation (Allo-SCT) in multiple myeloma is controversial mainly due to the relatively high non-relapse mortality (NRM). The aim with this retrospective single-center study was evaluate recent transplants particularly after conditioning treosulfan plus fludarabine (TreoFlu).